Paliperidone
Product manufactured by Mylan Institutional Inc.
Indications and Purposes
| 1 Indications And Usage Paliperidone Extended-Release Tablets Are An Atypical Antipsychotic Agent Indicated For Treatment Of Schizophrenia ( 1.1 ) Adults: Efficacy Was Established In Three 6-Week Trials And One Maintenance Trial. ( 14.1 ) Adolescents (ages 12-17): Efficacy Was Established In One 6-Week Trial. ( 14.1 ) Treatment Of Schizoaffective Disorder As Monotherapy And As An Adjunct To Mood Stabilizers And/or Antidepressants. ( 1.2 ) Efficacy Was Established In Two 6-Week Trials In Adult Patients. ( 14.2 ) 1.1 Schizophrenia Paliperidone Extended-Release Tablets Are Indicated For The Treatment Of Schizophrenia [see Clinical Studies (14.1) ] . The Efficacy Of Paliperidone Extended-Release Tablets In Schizophrenia Was Established In Three 6-Week Trials In Adults And One 6-Week Trial In Adolescents, As Well As One Maintenance Trial In Adults. 1.2 Schizoaffective Disorder Paliperidone Extended-Release Tablets Are Indicated For The Treatment Of Schizoaffective Disorder As Monotherapy And An Adjunct To Mood Stabilizers And/or Antidepressant Therapy [see Clinical Studies (14.2) ] . The Efficacy Of Paliperidone Extended-Release Tablets In Schizoaffective Disorder Was Established In Two 6-Week Trials In Adults. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Paliperidone |
|
ZINC4214700 |